Method of treatment of hemorrhagic disease using a factor VIIa/tissue factor inhibitor
View Patent ↗The present invention provides methods of treating hemorrhagic fevers where selective inhibitors of fVIIa/TF are used as a treatment for hemorrhagic fevers and have therapeutic effects which include ameliorating and/or preventing coagulopathy and inflammatory responses. These inhibitors include certain proteins which are part of a family termed Nematode-Extracted Anticoagulant Proteins (“NAPs”). Other inhibitors include Tissue Factor Pathway Inhibitor (“TFPI”) and TFPI analogs.
1. A method of treating a mammal suffering from a viral hemorrhagic fever, the method comprising administering an effective amount of AcaNAPc2 (SEQ ID NO: 3).
2. A method of treating a mammal suffering from a viral hemorrhagic fever, the method comprising administering an effective amount of AcaNAPc2/proline (SEQ ID NO: 4).
3. A method of treating a mammal suffering from a viral hemorrhagic fever, the method comprising administering an effective amount of tissue factor pathway inhibitor (TFPI).
4. The method of claim 1 wherein the viral hemorrhagic fever is caused by a Filoviridae virus.
5. The method of claim 1 wherein the viral hemorrhagic fever is caused by a Arenaviridae virus.
6. The method of claim 1 wherein the viral hemorrhagic fever is caused by a Bunyaviridae virus.
7. The method of claim 1 wherein the viral hemorrhagic fever is caused by a Flaviridae virus.
8. The method of claim 1 wherein the hemorrhagic fever is caused by Ebola virus.
9. The method of claim 2 wherein the viral hemorrhagic fever is caused by a Filoviridae virus.
10. The method of claim 2 wherein the viral hemorrhagic fever is caused by a Arenaviridae virus.
11. The method of claim 2 wherein the viral hemorrhagic fever is caused by a Bunyaviridae virus.
12. The method of claim 2 wherein the viral hemorrhagic fever is caused by a Flaviridae virus.
13. The method of claim 2 wherein the hemorrhagic fever is caused by Ebola virus.
14. The method of claim 3 wherein the viral hemorrhagic fever is caused by a Filoviridae virus.
15. The method of claim 3 wherein the viral hemorrhagic fever is caused by a Arenaviridae virus.
16. The method of claim 3 wherein the viral hemorrhagic fever is caused by a Bunyaviridae virus.
17. The method of claim 3 wherein the viral hemorrhagic fever is caused by a Flaviridae virus.
18. The method of claim 3 wherein the hemorrhagic fever is caused by Ebola virus.
19. The method of claim 1 where the mammal is a human.
20. The method of claim 2 where the mammal is a human.
21. The method of claim 3 where the mammal is a human.
22. The method of claim 4 where the mammal is a human.
23. The method of claim 5 where the mammal is a human.
24. The method of claim 6 where the mammal is a human.
25. The method of claim 7 where the mammal is a human.
26. The method of claim 8 where the mammal is a human.
27. The method of claim 9 where the mammal is a human.
28. A method of treating a mammal suffering from a viral hemorrhagic fever, the method comprising administering an amount of AcaNAPc2 (SEQ ID No.: 3) effective to ameliorate symptoms of said fever.
29. A method of treating a mammal suffering from a viral hemorrhagic fever, the method comprising administering an amount of AcaNAPc2/proline (SEQ ID No.:4) effective to ameliorate symptoms of said fever.
30. A method of treating a mammal suffering from a viral hemorrhagic fever, the method comprising administering an amount of tissue factor pathway inhibitor (TFPI) effective to ameliorate symptoms of said fever.
31. The method of claim 13 where the mammal is a human.
32. The method of claim 14 where the mammal is a human.
33. The method of claim 15 where the mammal is a human.
34. The method of claim 16 where the mammal is a human.
35. The method of claim 17 where the mammal is a human.
36. The method of claim 18 wherein the mammal is a human.